NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?
about
Obesity Disease and SurgeryReview article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease.Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?FT3/FT4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with euthyroidism and hypothyroidism.Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis.Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease.Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver DiseasePhase II clinical trial of phlebotomy for non-alcoholic fatty liver disease.Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease.Association between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease: A Single-Center Clinical Study.Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites
P2860
Q26822547-5DDEA63B-3734-4283-8C9F-A335FAE2AA66Q26998093-15FE6559-DD80-4F05-AC4E-2AF28D48A731Q29994538-306A00E6-6BB0-4D76-9704-F405D665C86FQ30412771-1810C12B-4181-46A9-AC48-44EDE12F8614Q33633689-C8BBD9D5-328E-4104-BA58-1567C512F61DQ33845489-24872F0D-FF7A-4AC1-820D-374EE2139C2AQ36561556-0FC32FAC-23F2-4388-8C5E-2ABB44703046Q36779293-F6681C13-1CD7-4907-9699-5C6B407CCD50Q37038722-360A5229-8F6F-4C7D-8D50-2A4B3F570897Q37285253-70B272B9-BF57-4BF9-9409-F5A78DFBCF67Q38066240-7B2EB53E-0F70-4AD0-AC26-05410206EADFQ38083661-9ED7AD74-5317-425F-8594-A6A31BAB5765Q38455474-F943E7AD-EDCF-4832-8902-69F24D6F99E2Q40039094-8127CBC4-6038-4030-9524-AA5680FEF72BQ48105587-0FCDBA53-C096-4F9F-BB34-235EEC80FECAQ54258283-D2DD53CE-9F6E-4045-92D2-4EAE84ED5362Q57568837-1CCA2423-BE41-46CA-AAB8-31902451A15B
P2860
NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
NAFLD in the absence of metabo ...... ctors for disease progression?
@en
NAFLD in the absence of metabo ...... ctors for disease progression?
@nl
type
label
NAFLD in the absence of metabo ...... ctors for disease progression?
@en
NAFLD in the absence of metabo ...... ctors for disease progression?
@nl
prefLabel
NAFLD in the absence of metabo ...... ctors for disease progression?
@en
NAFLD in the absence of metabo ...... ctors for disease progression?
@nl
P921
P356
P1476
NAFLD in the absence of metabo ...... ctors for disease progression?
@en
P2093
Yusuf Yilmaz
P356
10.1055/S-0032-1306422
P50
P577
2012-02-01T00:00:00Z